Purple Biotech Net Profit Margin 2014-2024 | PPBT

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Purple Biotech net profit margin from 2014 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Purple Biotech net profit margin from 2014 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$173B
Vertex Pharmaceuticals (VRTX)	$127.1B
Gilead Sciences (GILD)	$114.2B
Bristol Myers Squibb (BMY)	$112.1B
CSL (CSLLY)	$91B
Regeneron Pharmaceuticals (REGN)	$89.7B
GSK (GSK)	$74.4B
Argenex SE (ARGX)	$35.2B
Alnylam Pharmaceuticals (ALNY)	$35.2B
Biogen (BIIB)	$25.4B
BioNTech SE (BNTX)	$25.4B
Illumina (ILMN)	$24.2B
Moderna (MRNA)	$19.9B
BeiGene (BGNE)	$19.7B
Incyte (INCY)	$15.6B
Genmab (GMAB)	$14.8B
Insmed (INSM)	$13B
Vaxcyte (PCVX)	$13B
BioMarin Pharmaceutical (BMRN)	$12.6B
Sarepta Therapeutics (SRPT)	$12.2B
Bio-Techne Corp (TECH)	$12B
Exelixis (EXEL)	$10.1B
Exact Sciences (EXAS)	$10.1B
QIAGEN (QGEN)	$10B
Revolution Medicines (RVMD)	$9.9B
Intra-Cellular Therapies (ITCI)	$9.5B
Bio-Rad Laboratories (BIO.B)	$9.4B
Roivant Sciences (ROIV)	$8.7B
Repligen (RGEN)	$8.2B
Ascendis Pharma (ASND)	$7.8B